Sudarshan Pharma Industries Limited (SUDARSHAN)
Snapshot
Sudarshan Pharma Industries Limited closed at ₹32.20 on 4 Nov 2026. Data as of 4 Nov 2026.
Price
- Market Cap
- ₹798 Cr
Exchange activity4 Nov 2026
- Delivery
- 29.47%
- Price band
- 1 band close in ~20 sessions
Events
- Latest results
- Q2 FY27, filed 30 Oct 2026
Exchange data. Each figure as its own page shows it; the dates are the data's. Information only, not investment advice.
📈 Share price & events
Q2 FY27 results
Sudarshan Pharma Industries Limited reported Q2 FY27 results on 30 Oct 2026: revenue ₹217 Cr, and net profit ₹7.8 Cr; the operating margin was 9.5%.
| Q2 FY27 (₹ Cr) | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹217 | — | +24.4% |
| Operating profit | ₹20.6 | — | +29.4% |
| Net profit | ₹7.8 | — | +38.7% |
| EPS (₹) | 0.31 | — | +34.8% |
| Operating margin | 9.5% | — | — |
- H1 FY27 operating cash flow was negative despite a profit
Quality of profit: of pre-tax profit of ₹10.8 Cr, ₹8.9 Cr (82%) came from the core business and the rest from other income and one-off items.
Share price since the results: -14.1% (close before the filing to the latest close).
SUDARSHAN delivery percentage
NSE end-of-day data for
On Wed, 4 Nov 2026, 29.47% of the SUDARSHAN shares traded on NSE were taken to delivery. The stock has too few sessions on record for a normal to compare with. It closed at a price band (circuit) on 1 session in about the last 20.
Delivery in the last 5 sessions: 62.7% · 46.6% · 58.7% · 43.3% · 29.5%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Sudarshan Pharma Industries' Board has approved raising funds up to ₹72 Crores through the issuance of convertible warrants on a preferential basis to promoters Mr. Hemal Mehta and Mr. Sachin Mehta. Each warrant is convertible into 1 equity share of face value ₹1, priced pursuant to SEBI ICDR Regulations. The fundraise represents approximately 36.9% of the company's net worth (₹195 Cr), which could aid in deleveraging given its ₹392 Cr debt load (D/E of 2.01). The proposal remains subject to shareholder approval at an upcoming Extraordinary General Meeting (EGM).
- Fundraise of up to ₹72,00,00,000 via preferential convertible warrants approved by the Board
- Warrants to be issued to promoters Mr. Hemal Mehta and Mr. Sachin Mehta
- Each warrant is convertible into 1 equity share of face value Re 1
- Issue price to be determined according to SEBI ICDR Regulation 164
- Fundraise represents ~36.9% of the company's net worth of ₹195 Cr
Sudarshan Pharma Industries reported standalone revenue from operations of ₹20,551.81 lakhs for Q2 ended September 30, 2026, up 23% YoY from ₹16,708.63 lakhs. Standalone net profit grew 77% YoY to ₹779.51 lakhs compared to ₹440.03 lakhs in Q2 FY25. The company migrated from the BSE SME platform to the Main Boards of BSE and NSE on October 27, 2026. Additionally, the company announced the discontinuation of manufacturing operations at its Palghar unit to rationalize costs.
- Standalone revenue from operations reached ₹20,551.81 lakhs in Q2 FY27 vs ₹16,708.63 lakhs in Q2 FY26
- Standalone net profit increased by 77.1% YoY to ₹779.51 lakhs for the quarter ended September 30, 2026
- Company completed migration from BSE SME to BSE Main Board and NSE Main Board on October 27, 2026
- Discontinued manufacturing operations at the Palghar unit to cut losses and rationalize operating costs
- Allotted 48,11,730 equity shares following conversion of USD 1.5 million FCCBs at ₹30.19 per share
Company profile
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
